Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents

Asciminib is a first‐in‐class inhibitor of BCR::ABL1, specifically targeting the ABL myristoyl pocket. Asciminib is a substrate of CYP3A4 and P‐glycoprotein (P‐gp) and possesses pH‐dependent solubility in aqueous solution. This report summarizes the results of two phase I studies in healthy subjects...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoch, Matthias, Huth, Felix, Sato, Masahiko, Sengupta, Tirtha, Quinlan, Michelle, Dodd, Stephanie, Kapoor, Shruti, Hourcade‐Potelleret, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283742/
https://www.ncbi.nlm.nih.gov/pubmed/35616006
http://dx.doi.org/10.1111/cts.13285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283742/
https://www.ncbi.nlm.nih.gov/pubmed/35616006
http://dx.doi.org/10.1111/cts.13285

Ejemplares similares